News und Analysen
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo
Zoetis (ZTS) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q4 2023 Earnings CallFeb 13, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET
Operator
Source Fool.com
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today
It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and
2 Growth Stocks to Buy at a Discount
The stock market is on fire as 2024 kicks off. As a result, many investors might be reviewing their long-term financial goals as well as their plans for stock purchases. As always, it's best to
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (NYSE: ABBV) Humira. That's
2 Bargain Basement Stocks to Buy Now and Hold Forever
Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working
Is Vertex Pharmaceuticals Stock a Buy Now?
Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are
3 Stocks That Could Trounce the Market in 2024
Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.
Three Motley Fool contributors think
Could Vertex Pharmaceuticals Reach $500 in 2024?
Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
DexCom (DXCM) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q4 2023 Earnings CallFeb 08, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q4 2023 Earnings CallFeb 08, 2024, 6:45 a.m. ET
Andy Barnett
Source Fool.com
Prediction: 2 Stocks That Could Trounce the Market
Every investor wants to beat the market, but doing so is notoriously difficult. That's why many settle for matching the performance of some prominent index by buying the appropriate exchange-traded
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the
2 Healthcare Stocks to Buy Hand Over Fist in February
Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the
Centene (CNC) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Centene (NYSE: CNC)Q4 2023 Earnings CallFeb 06, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data
This High-Flying Stock Just Got Some Bad News: Should You Sell?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod